VTGN vs. AMLX, ATYR, CMPX, AQST, TECX, ATAI, TERN, PROK, ANNX, and GOSS
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Amylyx Pharmaceuticals (AMLX), Atyr PHARMA (ATYR), Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), Tectonic Therapeutic (TECX), Atai Life Sciences (ATAI), Terns Pharmaceuticals (TERN), ProKidney (PROK), Annexon (ANNX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.
Vistagen Therapeutics vs.
Vistagen Therapeutics (NASDAQ:VTGN) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 1.3% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Vistagen Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500.
Vistagen Therapeutics received 248 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 66.67% of users gave Amylyx Pharmaceuticals an outperform vote.
In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 1 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.89 beat Amylyx Pharmaceuticals' score of 1.11 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Amylyx Pharmaceuticals has a consensus target price of $7.33, indicating a potential upside of 100.36%. Given Amylyx Pharmaceuticals' higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Vistagen Therapeutics.
Amylyx Pharmaceuticals has higher revenue and earnings than Vistagen Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amylyx Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Vistagen Therapeutics' return on equity.
Summary
Amylyx Pharmaceuticals beats Vistagen Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTGN) was last updated on 3/30/2025 by MarketBeat.com Staff
